HUTCHMED Announces CHMP Opinion For Fruquintinib In Previously Treated Metastatic Colorectal Cancer Received By Takeda
HUTCHMED Announces CHMP Opinion For Fruquintinib In Previously Treated Metastatic Colorectal Cancer Received By Takeda
和黃醫藥公佈了武田收到的呋喹替尼治療以往治療的轉移性結直腸癌的CHMP意見
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade —
— 如果獲得歐盟批准，呋喹替尼將成爲十多年來第一種治療轉移性結直腸癌的新型靶向療法，無論生物標誌物狀況如何 —
— Positive opinion based on results from FRESCO-2 Phase III clinical trial —
— 根據 FRESCO-2 III 期臨床試驗結果得出的積極評價 —